10.25384/SAGE.8184704.v1
Meritxell Bellet
Meritxell
Bellet
Faten Ahmad
Faten
Ahmad
Rafael Villanueva
Rafael
Villanueva
Carolina Valdivia
Carolina
Valdivia
Julián Palomino-Doza
Julián
Palomino-Doza
Ada Ruiz
Ada
Ruiz
Xavier Gonzàlez
Xavier
Gonzàlez
Encarna Adrover
Encarna
Adrover
Analía Azaro
Analía
Azaro
Maria Valls-Margarit
Maria
Valls-Margarit
Josep Lluís Parra
Josep Lluís
Parra
Juan Aguilar
Juan
Aguilar
Maria Vidal
Maria
Vidal
Anastasi Martín
Anastasi
Martín
Joaquín Gavilá
Joaquín
Gavilá
Santiago Escrivá-de-Romaní
Santiago
Escrivá-de-Romaní
Antonia Perelló
Antonia
Perelló
Cristina Hernando
Cristina
Hernando
Ainhara Lahuerta
Ainhara
Lahuerta
Pilar Zamora
Pilar
Zamora
Victoria Reyes
Victoria
Reyes
María Alcalde
María
Alcalde
Helena Masanas
Helena
Masanas
Pamela Céliz
Pamela
Céliz
Isabel Ruíz
Isabel
Ruíz
Miguel Gil
Miguel
Gil
Miguel Àngel Seguí
Miguel Àngel
Seguí
Lorena de la Peña
Lorena
de la Peña
InhibCDK-Supplementary_Material_v2_01012019 – Supplemental material for Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
SAGE Journals
2019
CDK inhibitors
palbociclib
ribociclib
breast cancer
2019-05-10 12:00:00
Journal contribution
https://sage.figshare.com/articles/journal_contribution/InhibCDK-Supplementary_Material_v2_01012019_Supplemental_material_for_Palbociclib_and_ribociclib_in_breast_cancer_consensus_workshop_on_the_management_of_concomitant_medication/8184704
<p>Supplemental material, InhibCDK-Supplementary_Material_v2_01012019 for Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication by Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquíín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar Zamora, Victoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí and Lorena de la Peña in Therapeutic Advances in Medical Oncology</p>